Evidence map›Paper›PMID 30077942›Full record

ReviewJournal of the neurological sciences2018

Acute hypertensive crisis and severe headache after concurrent use of armodafinil and tranylcypromine: Case report and review of the literature.

Connor J Kinslow, Steven D Shapiro, Michael F Grunebaum, Eliza C Miller

Abstract readCase ReportsReview
In one paragraph

Review in Journal of the neurological sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Drug Interactions With Excessive Daytime Sleepiness Treatments.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Connor J KinslowCollege of Physicians and Surgeons, Columbia University Medical Center, 630 W 168th St, New York, NY 10032, USA.
Steven D ShapiroDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, 710 West 168th Street, New York, NY 10032, USA.
Michael F GrunebaumNew York State Psychiatric Institute, Department of Psychiatry, College of Physicians and Surgeons, Division of Molecular Imaging and Neuropathology, Columbia University Medical Center, 1051 Riverside Dr, New York, NY 10032, USA.
Eliza C MillerDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, 710 West 168th Street, New York, NY 10032, USA. Electronic address: ecm2137@cumc.columbia.edu.

Funding

Institutional Career Development CoreKL2TR001874 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GENKINGER, JEANINE M., SHIMBO, DAICHI · 2016 to 2025
$13.6M
NCATS NIH HHS KL2 TR001874
6 · The paper itself

Abstract

Concurrent use of modafinil or armodafinil with monoamine oxidase inhibitors (MAOIs) is contraindicated due to a theoretical risk of drug synergism and acute hypertensive episodes. However, few data are available to substantiate that risk, and several case studies have suggested that the combination is safe. To our knowledge, we present the first case of a patient treated concurrently with armodafinil and tranylcypromine. The patient developed an acute hypertensive crisis with severe headache, nausea, blurry vision, and neck stiffness. Her symptoms corresponded with the predicted pharmacokinetic and pharmacodynamic response. She was also taking brexpiprazole, which could have contributed to her underlying symptoms. However, limited data suggest that the single combination of brexpiprazole with armodafinil or MAOIs would be safe. Upon review of the literature, two out of seven patients, including our own, treated concurrently with modafinil or armodafinil and an MAOI developed an adverse reaction. Physicians should exercise caution if using these classes of drugs together.

Indexed as

AdultDrug SynergismDrug Therapy, CombinationFemaleHeadacheHumansHypertensionModafinilMonoamine Oxidase InhibitorsTranylcypromineWakefulness-Promoting AgentsModafinilMonoamine Oxidase InhibitorsTranylcypromineWakefulness-Promoting Agents

Identifiers

PMID30077942
PMCPMC6446082

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.